Bridging Connections and Insights from Investment Conferences

Bridging Connections and Insights from Investment Conferences

By Punit Dhillon, CEO and President of OncoSec Medical Incorporated

After the conclusion of several conferences this past month, I’ve had time to reflect on key takeaways and principal trends emerging in the healthcare sector. Despite less than stellar market conditions, speakers at conferences (such as J.P. Morgan 2016 and Bio CEO) and ancillary events remained optimistic and highlighted important insights into the future of healthcare. After a busy schedule with non-stop meetings and presentations, I returned home confident in OncoSec’s place in the burgeoning cancer immunotherapy landscape.

SAN DIEGO, CA — June 14, 2012 — OncoSec Medical Incorporated (OTCBB: ONCS, a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announced it will be presenting at a series of investor and scientific conferences in upcoming weeks.

Investor Conferences

Punit Dhillon, President and CEO, will be presenting a corporate overview of OncoSec, including its portfolio and investment highlights, at the following conferences:

Bio International Convention, Boston, MA, June18-21, 9:00 am ET

Marcum MicroCap Conference, New York, NY, June 20, 11:30 am ET
A live and archived webcast of Mr. Dhillon’s presentation will be accessible on the OncoSec website, www.OncoSec.com. Please allow 15 minutes prior to the presentation to allow for any softwaredownloads.

OneMedForum NY 2012, New York, NY, July 12, Time to be confirmed

Scientific Conferences

In addition, OncoSec will be providing an update on its cancer immunotherapy program and on-going clinical trials at the following conferences:

2nd European Post-Chicago Melanoma Meeting, Munich, Germany, June 21-22, 9:48 CET
Presented by Dr. Adil Daud MD, Principal Investigator

10th Annual Vaccines Research and Development: All Things ConsideredConference, San Francisco, CA, July 10, 11:05 am PT
Presented by Punit Dhillon, CEO

The Company will also be presenting a poster containing data from a Phase III study of the OMS ElectroChemotherapy therapy at the following conference:

8th International Conference on Head and Neck Cancer, Toronto, Canada, July 22-24

About OncoSec Medical Inc.

OncoSec Medical Incorporated is a biopharmaceuticalcompany developing advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent apotential solution for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from traditional cancer treatments. OncoSec’s core technology is based upon its proprietary use of an electroporation platform, to dramatically enhance the delivery and uptake of a locally delivered DNA-based immuno-cytokine or a chemotherapeutic agent. Treatment of various solid cancers using these targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy targeting lethal skin cancers. More information is available at www.oncosec.com.

* * *

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause ourresults to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

SAN DIEGO, CA, May 29, 2012 — OncoSec Medical Inc. (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System(OMS) ElectroOncology therapies to treat solid tumor cancers, issued the following letter to Shareholders today:

Dear Shareholder:
As we near the mid-point of 2012, OncoSec is successfully executing on its objectives for the year. I want to review the key developments so you can see why all of us at OncoSec are so excited.

Financial Update

  • Strengthened balance sheet: OncoSec recently raised $7.75 million through a public offering underwritten by Rodman & Renshaw, with Roth Capital Partners acting as an advisor. We are now well financed to continue our promising clinical development programs. We currently have over $6.5 million in cash reserves to fund operations, which should be sufficient to complete our current studies.

Clinical Update
We are executing our clinical development plan based on our novel, first-in-class OMS ElectroImmunotherapy platform for the treatment of rare and deadly skin cancers including metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma.

  • OMS-I100: We initiated and enrolled several patients in OMS-I100, a Phase II study for the treatment of metastatic melanoma led by the University of California at San Francisco, with additional sites at the John Wayne Cancer Institute in Santa Monica and Lakeland Comprehensive Cancer Center in Lakeland, Florida. We expect to report interim clinical data before year end.
  • OMS-I110: We initiated and enrolled several patients in OMS-I110, a Phase II study for the treatment of Merkel cell carcinoma led by the University of Washington and the Fred Hutchinson Cancer Center in Seattle, Washington. We expect to report interim clinical data before year end.
  • OMS-I120: We aim to initiate and begin enrolling patients in OMS-I120, a Phase II study for the treatment of cutaneous T-cell lymphoma (CTCL) by year-end. This study will be led by the University of California at San Francisco and include multiple centers across the US.
  • Expansion of technology platform: We are pursuing clinical and regulatory development of our OMS ElectroChemotherapy in the U.S., Europe and Asia, including the development of new indications for ElectroChemotherapy. The last several months have demonstrated our ability to create incremental value from our advanced-stage OMS ElectroChemotherapy program for the treatment of primary and recurrent localized solid tumors. Since the acquisition of a clinical data set of over 400 patients, we have compiled, reviewed, and analyzed the data and presented preliminary results from a Phase IV European head & neck cancer trial and Phase I/II breast cancer trial. The preliminary data sets from the completed Phase III recurrent head and neck cancer studies carried out in the U.S. are now being analyzed, and we intend to present this data at the 5th International Head and Neck Cancer Conference taking place July 21-25. We are defining a regulatory path with the FDA forclinical development of advanced stage skin cancer and other solid tumor indications. In addition, we are advancing a commercialization strategy focused on creating regional partnerships or establishing a global partner to develop the market potential for OMS ElectroChemotherapy in Europe, Asia and other emerging markets.

Corporate Update

  • Patent portfolio expansion. We are developing new applications of our OMS ElectroOncology for treating solid tumors and metastatic disease, with the goal of expanding our market opportunities and establishing additional patents to maintain our dominance in these areas.
  • Gaining leadership position and creating awareness: We have been able to build physician, partner, and patient awareness of the clinical development of OMS ElectroImmunotherapy for the treatment of metastatic melanoma and Merkel cell carcinoma through the media. These publications include: Xconomy, Medical Device & Diagnostic Industry, Manufacturing Chemist, and the San Diego Business Journal. OMS ElectroImmunotherapy was also featured as a “revolutionary cancer treatment” for Merkel cell carcinoma by a local NBC News affiliate in Seattle, Washington. We continue our proactive outreach to inform relevant audiences of technology and business opportunities.

OncoSec sees the initial market for its OMS ElectroImmunotherapy exceeding $500 million in the U.S. alone. Melanoma andother skin cancers are deadly diseases with very limited treatment options (i.e. limited competition). We have a highly focused effort to develop a new generation of immunotherapy products to provide better care to these patients and we are passionate about the progress of our programs.

I thank you for your ongoing support as we work toward our goal of becoming the preeminent developer of targeted oncology therapies. Ilook forward to updating you on our continued progress in the year ahead.

Best regards,
Punit Dhillon
President and CEO

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapieshave achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec’s Facebook , Twitter, and LinkedIn sites.

* * *

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause ourresults to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

SAN DIEGO, CA, May 29, 2012 — OncoSec Medical Inc. (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that Punit Dhillon,President and CEO at OncoSec, will be presenting at BioFinance 2012 in Toronto, Canada, on Wednesday, May 30, 2012.

BioFinance 2012
St. Andrew’s Club & Conference Centre
150 King Street West
Toronto, Canada M5H 1J9
May 29-30, 2012

OncoSec Presentation
Wednesday, May 30, 2012
11:00am ET

BioFinance 2012 is the Canadian forum for some of the most innovative minds in the life sciences industry today, with attendance ranging from company CEO’s, CFO’s and senior executives, institutional and private equity investors from the US and Canada, industry analysts, corporate finance executives and experts from pharmaceutical, agriculture biotech communities in Canada, the US and Europe. Program presentations range from publicly traded and major private companies to early-stage seed opportunities. Company presentations will span a range of industries including biologics, medical devices, drug delivery, vaccines, diagnostics, bio-energy, green technologies, bio materials, industrial biotech, and research services. These companies will also highlight their solid potential, strong management and funding requirements in the $2-$100 million range.

To arrange a meeting with management please contact AdamHoldsworth,
The Investor Relations Group 212-825-3210 aholdsworth@investorrelationsgroup.com

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapieshave achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec’s Facebook , Twitter, and LinkedIn sites.

* * *

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause ourresults to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

SAN DIEGO, CA, May 10, 2012 — OncoSec Medical Inc. (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that Punit Dhillon,President and CEO at OncoSec, will be presenting at the VC in the OC investor conference on May 15, 2012.

VC in the OC
HyattRegency Huntington Beach
21500Pacific Coast Highway
Huntington Beach, CA 92648
May 15, 2012

OncoSec Presentation
4:25pm PT

VC in the OC is the first of two signature events held by OCTANe each year. OCTANe is a not-for-profit organization whose members represent technology executive leaders, entrepreneurs, investors, venture capitalists, academics and strategic advisors in the Orange County area. In the past years, some of Orange County’s top venture-backed companies have made presentations at VC in the OC. This year’s program will feature fourteen investment presentations from highly qualified start-up and growth companies that are seeking Seed, Series A, or later stage venture capital investment.

To arrange a meeting with management please contact AdamHoldsworth,
The Investor Relations Group 212-825-3210 aholdsworth@investorrelationsgroup.com

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapieshave achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec’s Facebook , Twitter, and LinkedIn sites.

* * *

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause ourresults to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

SAN DIEGO, Ca, March 28, 2012 — OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, announced today the closing of the sale to institutional investors of an aggregate of 31,000,000 shares of its common stock at $0.25 per share in a registered public offering. Additionally, investors received Warrants to purchase up to 31,000,000 shares of common stock at an exercise price of $0.35 per share for a term of five years.

The gross proceeds of the offering were $7.75 million and net proceeds, after deducting the placement agent’s fee and estimated offering expenses payable by OncoSec, were approximately $7.2million.

OncoSec intends to use proceeds from the offering for general corporate purposes, including clinical trial expenses and research and development expenses.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ:RODMNews), acted as the exclusive placement agent for the transaction. Roth Capital Partners, LLC served as financial advisors to the Company in the offering.

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapieshave achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec’s Facebook , Twitter, and LinkedIn sites.

* * *

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause ourresults to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

SAN DIEGO, Ca, March 26, 2012 — OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, announced today that it has entered into definitive agreements with institutional investors to purchase $7.75 million of securities in a registered public offering. OncoSec has agreed to sell to institutional investors an aggregate of 31,000,000 shares of its common stock at $0.25 per share. Additionally, investors will receive Warrants to purchase up to 31,000,000 shares of common stock at an exercise price of $0.35 per share for a term of five years.

The gross proceeds of the offering are expected to be $7.75 million. Net proceeds, after deducting the placement agent’s fee and other estimated offering expenses payable by OncoSec, are expected to be approximately $7.2 million.

OncoSec intends to use proceeds from the offering for general corporate purposes, including clinical trial expenses and research and development expenses.

“We are pleased to have the endorsement of several healthcare institutional investors that recognize the value of our clinical development plan,” said Punit Dhillon, President and CEO.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ:RODMNews), acted as the exclusive placement agent for the transaction.

The offering is expected to close on March 28, 2012, subject to customary closing conditions.

The securities described above are being offered by OncoSec pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission, or the SEC. A prospectus supplementrelated to the offering will be filed with the SEC. The securities may only be offered by means of a prospectus. Copies of the prospectus and prospectus supplement can be obtained directly from Rodman & Renshaw, LLC at info@rodm.com, or by mail at 1251 Avenue of the Americas, 20th floor, New York, NY 10020 and at the SEC’s website at www.sec.gov. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our common stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapieshave achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec’s Facebook , Twitter, and LinkedIn sites.

* * *

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause ourresults to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

SAN DIEGO, CA, February 8, 2012 — OncoSecMedical Inc. (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that Punit Dhillon,President and CEO at OncoSec, will be presenting at the 14th Annual BIO CEO & Investor Conference in New York, February 13-14, 2012.

14th Annual BIO CEO & Investors Conference
The Waldorf-Astoria Hotel
301 Park Avenue
New York, NY 10022
February 13-14, 2012

OncoSec Presentation
February 13, 2012
9:30am ET

The Bio CEO & Investor Conference is a leading investor conference focused on both established and emerging publically traded companies attracting institutional investors, industry analysts and biotechnology executives who have the opportunity to meet and influence the future landscape of the biotechnology industry.

A live and archived webcast will be accessible on OncoSec’s website www.OncoSec.com. Please allow 15 minutes prior to the presentation to allow for any software downloads.

To arrange a meeting with management please contact AdamHoldsworth,
The Investor Relations Group 212-285-3210 aholdsworth@investorrelationsgroup.com

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapieshave achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec’s Facebook , Twitter, and LinkedIn sites.

* * *

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause ourresults to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

SAN DIEGO, CA, January 18, 2012 — OncoSec Medical Incorporated (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System(OMS) ElectroOncology therapies to treat solid tumor cancers, presented its corporate strategy for 2012 and reported on progress since launch of the company lastyear at the Biotech Showcase and OneMedForum conferences held January 9-13 in San Francisco, CA.

“Despite a financially challenging year, 2011 was a pivotal and an exciting year for us, and our shareholders, as we laid the foundation for OncoSec’s success.” Said Punit Dhillon, President and CEO. “If we scored ourselves based on the milestones set forth by the OncoSec Board of Directors and management team, then 2011 was a resounding success. We now look forward to taking the next critical steps as a clinical development company with three cancer immunotherapy clinical studies beginning. It is our goal to address indications with substantial unmet medical needs and therefore allow patients with lethal skin cancers to evaluate eligibility in the pioneering OncoSec treatment. Unfortunately these are indications that have not seen new satisfactory options for patients in quite some time.”

ENROLMENT SOON TO BE INITIATED FOR OMS ELECTROIMMUNOTHERAPY CLINICAL PROGRAMS AT LEADING ACADEMIC CANCER INSTITUTES

The Company established a robust clinical development plan based on its novel, first-in-class OMS ElectroImmunotherapy treatment platform for the treatment of rare and deadly skin cancers, including (1) metastatic melanoma; (2) Merkel cell carcinoma; and (3) cutaneous T-cell lymphoma. OMS ElectroImmunotherapy employs electroporation to deliver, directly into the patient’s own cells, a gene which expresses interleukin-12 (DNA-based IL-12), a potent, naturally occurring protein that is central to the regulation of the bodies cellular anti-cancer immune responses. Preclinical and Phase I studies have shown that the therapy is safe, without toxic side effects, and has resulted in immuneresponses that produced both a local and systemic response against cancerous lesions. Positive clinical data of DNA-based IL-12, the first-ever to demonstrate electroporation-mediated delivery of a DNA plasmid designed to express a therapeutic protein in humans, were presented at the 2011 Annual Meeting of the American Society of Clinical Oncology. In the Phase I human study, 15% of patients demonstrated 100% clearance of distant, untreated metastatic melanoma tumors; in retrospect only 0.25% would be expected to spontaneous resolve on their own if left untreated. If OncoSec’s Phase II trials further validate this evidence, the DNA-based IL-12 electroimmunotherapy platform would represent an important advancement in the treatment of both local and metastatic cancers. All three Phase II studies will be physician-sponsored clinical trials.

“With initiation of these three Phase II open label, multi-center clinical trials, OncoSec will demonstrate its commitment to developing revolutionary therapies for rare skin cancers.” Said Mr. Dhillon. “Despite recent drug approvals for metastatic melanoma, there still remains a significant need for more durable and safer treatment alternatives. In the case of Merkel cell carcinoma and cutaneous T-cell lymphoma, little, if any, treatment options are available for this population of patients destined to die with their disease.”

Phase II Melanoma Trial (OMS-I100)

Over 9,000 people die from melanoma each year in the U.S. alone and it is estimated that the rate of growth for this deadly cancer will increase to over 150,000 new cases per year by 2020. OncoSec’s melanoma trial, entitled “Phase II trial of intratumoral pIL-12 electroporation in advanced stage cutaneous and in transit malignant melanoma,” will be an open-label, multicenter trial. The primary endpoint is objective response rate (local and distant) at six months. Secondary trial endpoints include time to objective response (complete and partial responses), duration of distant response and overall survival. Current outcomes for melanoma treated using standard chemotherapies alone, or new biologic and small molecule treatmentapproaches, have not proved encouraging because of low response rates, short duration, high toxicity, high refractory rates, and severe side effects, while only providing a modest improvement in survival.

Phase II Merkel Cell Carcinoma Trial (OMS-I110)

Merkel cell carcinoma is a lethal but rare form of skin cancer affecting approximately 1,500 people in the U.S. each year. Current outcomes to chemotherapy treatment have demonstrated short-lived responses with no clear impact on overall survival due to the 33% mortality rate inherent with Merkel cell cancer. OncoSec’s clinical trial, entitled “A Phase II study of intratumoral injection of interleukin-12 plasmid and in vivo electroporation in patientswith Merkel cell carcinoma,” is a single dose, open-label, multicenter trial. The study’s endpoint is DNA-based IL-12 gene expression in tumor tissue at three to four weeks post-treatment. Secondary endpoints will evaluate objective response rates, time to relapse or progression and overall survival. This study will evaluate the safety and tolerability of DNA-based IL-12 as a treatment for Merkel cell carcinoma and aims to further validate the findings of the previously referenced Phase I trial in metastatic melanoma patients. The recent discovery of a Merkel cell polyomavirus, coupled with strong evidence suggesting that patients with Merkel cell carcinoma carry significant immune dysfunction in the tumor microenvironment suggests that an immunotherapy, such as DNA-based IL-12, may be effective at treating this disease.

Phase II Cutaneous T-Cell Lymphoma (OMS-I120)

OncoSec’s electroimmunotherapy is a potential new treatment for patients suffering from cutaneous T-cell lymphoma, or CTCL. This cancer affects approximately 3,000people in the U.S. each year. Today’s systemically delivered treatment methods typically result in toxicities that preclude their long-term use for this chronic life-altering disease. Some immunotherapies have shown promising therapeutic benefit. For example, recombinant human IL-12 (rhIL-12) has been shown to have greater than 40% response rate in Phase I and II clinical trials. However, side effects of this systemically delivered therapy proved to be intolerable for most patients, and chronic use of rhIL-12 resulted in drug resistance. OncoSec’s OMS ElectroImmunotherapy will locally deliver low-dose DNA-based IL-12 into the cancerous lesion with the goal of inducing a systemic immune response capable of destroying cancerous cells while avoiding toxicities and any chance of resistance.

Strategic goals for OncoSec’s OMS ElectroImmunotherapy program in 2012:

  • Initiate and enroll (OMS-I100) Phase II melanoma study led by the University of California at San Francisco along with other cancer centers across the US.
  • Initiate and enroll (OMS-I110) Phase II Merkel Cell Carcinoma study led by the University of Washington (Fred Hutchinson Cancer Center) and University of California at San Francisco.
  • Initiate and enroll (OMS-I120) Phase II Cutaneous T-Cell Lymphoma (CTCL) led by the University of California at San Francisco along with multiple centers across the US.
  • Complete and report interim analysis of clinical data from each of the clinical studies.
  • Finalize sponsor IND based on positive Phase II clinical results in consultation with regulatory authorities.

OMS ELECTROCHEMOTHERAPY CONTINUES TO SHOW IMPRESSIVE DATA AND NEAR TERM COMMERCIALIZATION THROUGH POTENTIAL REGIONAL PARTNERSHIPS AND/OR A GLOBAL PARTNER

This past year also demonstrated the Company’s ability to continue to create value from its advanced-stage OMS ElectroChemotherapyprogram for the treatment of primary and recurrent localized solid tumors. Since the acquisition of a clinical data set of over 400 patients, OncoSec has compiled, reviewed, and analyzed the data and presented preliminary resultsfrom it’s Phase IV European head & neck cancer trials and Phase I/II breast cancer trial. The preliminary data sets from the completed Phase III recurrent head and neck cancer studies carried out in the U.S. are now being analyzed, and the Company expects to share this information with potential partners for the continued development of this program.

“With positive results presented from the completed Phase I/II breast cancer and preliminary Phase IV skin and head and neck cancer studies in 2011, OMS ElectroChemotherapy has demonstrated the clinical benefit for patients with quite manageable side effects,” said Mr. Dhillon. “We strongly believe in the clinical relevance of our therapeutic approach and believe these results demonstrate tolerability and efficacy and point to the combinability of this novel treatment approach with current available therapies for the management of local tumors. Clinical experience from these programs supports the uniqueness of OMS ElectroChemotherapy in its ability to achieve selective destruction of cancerous tumors while sparing healthy normal tissue including highly vascularized and innervated surrounding structures, providing physicians with an important flexible treatment alternative.”

Strategic goals for OMS ElectroChemotherapy in 2012:

  • Finalize and present data analysis of completed Phase III recurrent head and neck cancer study.
  • Finalize and present data analysis of completed Phase IV recurrent and primary head and neck cancer study.
  • Finalize and present data analysis of completed Phase IV recurrent and primary skin cancer study.
  • Establish regulatory path with the FDA for clinical development of advanced stage skin cancer and other solid tumor targets in the US to achieve licensure.
  • Consider out-licensing opportunities through potential regional partnerships or a global partner to maximize near term commercialization opportunities in Europe, Asia and potentially other emerging markets.

FORMATION PHASE COMPLETE; CONTINUED COMMITMENT ON EFFICIENT OPERATIONS

The formation of OncoSec in 2011 occurred through the acquisition of certain non-DNA vaccine technology and intellectual propertyrelating to the Company’s OMS ElectroOncology therapies for treating solid tumor cancers. With seed capital secured, the Company moved quickly to attract and acquire an experienced and respected management team and scientific advisory board. The Company then established a clinical development plan based on its novel, first-in-class OMS ElectroImmunotherapy treatment platform for the treatment of deadly skin cancers, including metastatic melanoma, Merkelcell carcinoma and cutaneous T-cell lymphoma.

The Company will continue to build product value throughnext generation devices and drugs and generate additional intellectual property organically or through other in-licensing opportunities. In 2011, OncoSec completed its in-house capabilities to build, maintain and develop its own devices. In 2012, the Company expects to continue to boost its capabilities by meeting additional stringent quality assurance standards and increasing manufacturing capabilities for its ongoing and future clinical trials through additional efficiencies and ability to scale up production as needed to support potential partners.

“I am pleased that we have been able to leverage a large amount of existing investment into the OMS ElectroOncology platform to operate not only efficiently but resourcefully, I fully expect the Company to stay lean and agile while having the flexibility to outsource specific activities, where and when required, thereby allowing the Company to hold control over its operating expenditures.” said Mr. Dhillon.

Strategic goals for organizational efficiencies in 2012:

  • Complete ISO13485 qualification and certification
  • Acquire CE Mark of OncoSec Medical System
  • Complete additional in-licensing opportunities
  • Make additional hires in manufacturing, R&D, and administration to reflect program and business requirements

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapieshave achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec’s Facebook , Twitter, and LinkedIn sites.

* * *

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause ourresults to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

SAN DIEGO, CA, January 5, 2012 — OncoSec Medical Inc. (OTCBB:ONCS), which is developing its advanced-stage Oncology Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that representatives of OncoSec’s executive management team will be attending the 30th Annual JP Morgan Healthcare Conference in San Francisco, January 9-11. In addition, Punit Dhillon, President and CEO, will be presenting a company update at two investor conferences held concurrently with the JP Morgan Conference.

30th Annual JP Morgan Global Healthcare Conference
The Westin St. Francis
335 Powell Street
San Francisco, CA
January 9-12, 2012

OneMedForum
Sir Francis Drake Hotel
450 Powell Street
San Francisco, CA 94102
January 9-12, 2012

OncoSec Presentation
January 10, 2012
11:45AM PT

BioTech Showcase
Parc 55 Wyndham
55 Cyril Magnin Street
San Francisco, CA 94102
January 9-11, 2012

OncoSec Presentation
January 11, 2012
4:00PM PT

Live and archived webcast will be accessible on OncoSec’s website www.oncosec.com please allow 15 minutes prior to the beginning of the presentation to allow for any software downloads.

To arrange a meeting with management please contact Adam Holdsworth,
The Investor Relations Group 212-285-3210 aholdsworth@investorrelationsgroup.com

The prestigious JP Morgan Global Healthcare Conference is one of the world’s largest premier life sciences oriented conference that attracts thousands of healthcare and life science business executives, established industry thought leaders, emerging companies, innovative technology creators and financiers worldwide to San Francisco.

OneMedForum, currently in its 5th year provides an efficient means for industry business and investment professionals to meet managing executives of emerging and rapid growth life science companies who are shaping the changing future of healthcare. The forum will offer presentations from companies of various life science facets, panels and workshops to provide attendees with strategic and practical insight.

Currently in its 4th year, BioTech Showcase will feature presentations by over 200 public and private life science companies to an audience of both public and private investors, business development executives and professional advisors who are interested in creating potential investment opportunities and collaborations.

About OncoSec Medical Inc.

OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapieshave achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec’s Facebook , Twitter, and LinkedIn sites.

* * *

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause ourresults to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


1 2 3
Real Time Web Analytics